Hardman & Co issues research report

RNS Number : 0088D
Allergy Therapeutics PLC
21 October 2015
 

 

Hardman & Co issues research report on Allergy Therapeutics

 

Pollinex Quattro driving US market opportunity. AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. It has an underlying profitable and cash generative business despite its lead product being available only on a 'Named Patient' basis. However, protocols agreed with EU and US regulators are in place to get Pollinex Quattro approved as a biological. The US opportunity is enormous and only two players have short-course treatments. There is a valuation mis-match between AGY and its peers, which either have no growth or little marketing experience, which provides scope for considerable upside towards our risk-adjusted DCF valuation of 93p per share.

 

Please click here for the full report:

 

http://www.hardmanandco.com/system/files/research_papers/Allergy%20Therapeutics%20Initiation%2021.10.15b.pdf

 

 

To contact us:   

Hardman & Co

11/12 Tokenhouse Yard 

London

EC2R 7AS

Contact: Mark Brewer mb@hardmanandco.com

Martin Hall  mh@hardmanandco.com

Telephone: +44 20 7929 3399

Follow us on Twitter @HardmanandCo

 

 

 

www.hardmanandco.com

 

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge.  Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

 

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

 

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies.  It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAXFLFLEBFZFBE
UK 100

Latest directors dealings